Background
Lung cancer is the most common malignancy and the leading cause of cancer death around the world, with an estimated 2,093,876 new cases and 1,761,007 deaths in 2018 worldwide [
1]. The major histological subtype of lung cancer is non-small cell lung cancer (NSCLC), which mainly includes adenocarcinoma and squamous cell carcinoma, and accounts for approximate 80% of lung cancers [
2]. Except the NSCLC patients which are diagnosed at early stages and could be cured by surgical resection, most NSCLC patients still have poor outcomes with the 5-year survival rate of about 20% [
3]. Thus, it is of paramount importance to reveal the underlying molecular mechanisms contributing to the tumorigenesis and progression of NSCLC in order to develop novel therapeutic strategies for NSCLC [
4‐
6].
Accumulating evidences have revealed that most of human genome is transcribed, but only about 2% of human genome encode for proteins [
7]. Therefore, most of human transcripts don’t encode for proteins. Among these non-coding transcripts, long noncoding RNAs (lncRNAs) have gradually attracted people’s attention [
8‐
12]. LncRNA is a class of non-coding transcripts with more than 200 nucleotides in length and limited protein coding potential [
13‐
15]. Many lncRNAs are revealed to play important roles in various pathophysiological processes [
16‐
19]. As to tumors, lncRNAs have been reported to regulate almost every aspect of biological behaviors of cancer cells, including cell proliferation, apoptosis, senescence, autophagy, migration, invasion, and so on [
20‐
25]. Furthermore, many lncRNAs are dysregulated in various cancers and associated with early diagnosis and/or prognosis [
26‐
28].
Several lncRNAs have been reported to have oncogenic or tumor suppressing roles in NSCLC. LncRNA MALAT1 is a positive marker of lung cancer metastasis [
29]. LncRNA PVT1 is reported to promote NSCLC cell proliferation [
30]. LncRNA BANCR is reported to promote NSCLC metastasis [
31]. LncRNA MIR22HG is reported to inhibit cell survival [
32]. LncRNA P53RRA is reported to promote ferroptosis and apoptosis [
33]. LncRNA MUC5B-AS1 is reported to promote metastasis [
34]. LncRNA linc00460 is reported to promote cell migration [
35]. LncRNA LINC00473 is reported to promote lung cancer tumor growth [
36]. Although the expression and function of these lncRNAs are studied in NSCLC, most lncRNAs transcribed from human genome are functionally unclear in NSCLC [
37]. LncRNA PXN-AS1-L is a recently identified lncRNA, which is upregulated in hepatocellular carcinoma (HCC) and promoted HCC tumorigenesis via up-regulating PXN [
38]. However, the expression, roles, and mechanisms of action of lncRNA PXN-AS1-L in NSCLC are still unknown.
In this study, we aimed to elucidate the expression pattern of lncRNA PXN-AS1-L in NSCLC via measuring PXN-AS1-L expression in noncancerous lung tissues, NSCLC tissues, NSCLC bone metastases tissues, normal bronchial epithelial cell line, and human NSCLC cell lines. We also investigated the biological functions of PXN-AS1-L in NSCLC using in vitro and in vivo gain-of-function and loss-of-function assays. Moreover, we explored the molecular mechanisms mediating the roles of PXN-AS1-L in NSCLC.
Methods
Cell culture and treatment
The human normal bronchial epithelial cell line 16HBE, human NSCLC cell lines NCI-H1975, A549, NCI-H1299, and SK-MES-1 were obtained from Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). 16HBE cells were cultured in Dulbecco’s Modified Eagle’s Medium (Invitrogen, Carlsbad, CA, USA). NCI-H1975 and NCI-H1299 cells were cultured in RPMI-1640 Medium (Invitrogen). A549 cells were cultured in F-12K Medium (Invitrogen). SK-MES-1 cells were cultured in Eagle’s Minimum Essential Medium (Invitrogen). All the cells were maintained in the above described medium supplemented with 10% fetal bovine serum (Invitrogen) in a humidified incubator at 37 °C with 5% CO2. Where indicated, NSCLC cells were treated with 50 µM α-amanitin (Sigma-Aldrich, Saint Louis, MO, USA) for 0–24 h as shown in the article.
Human tissue specimens
Sixty-six pairs of NSCLC tissues and adjacent noncancerous lung tissues, and ten NSCLC bone metastases tissues were acquired from NSCLC patients who underwent surgery at the General Hospital of Chinese People’s Liberation Army (Beijing, China). All the tissues were diagnosed and histologically confirmed by two pathologists. The resected specimens were immediately frozen in liquid nitrogen and stored at − 80 °C until use. The study was approved by the ethics committee of the General Hospital of Chinese People’s Liberation Army (Beijing, China) and written informed consent was obtained from all patients.
Plasmids construction and transfection
PXN-AS1-L overexpression plasmid pcDNA3.1-PXN-AS1-L was constructed as previously described [
38]. Briefly, PXN-AS1-L full-length transcript was PCR amplified by Thermo Scientific Phusion Flash High-Fidelity PCR Master Mix (Thermo-Fisher Scientific, Waltham, MA, USA) and subcloned into the
BamH I and
EcoR V sites of pcDNA3.1 plasmid (Invitrogen). The primers sequences were: 5′-GGTACCGAGCTCGGATCCTCGCGTTGGAGGAGCTTG-3′ (forward) and 5′-GCCACTGTGCTGGATATCCTACAAAAAAAATTTATTTAATAAAA-3′ (reverse). The cDNA oligonucleotides suppressing PXN-AS1-L or PXN expression were designed and synthesized by GenePharma (Shanghai, China). After annealing, double strand oligonucleotides were inserted to the SuperSilencing shRNA expression plasmid pGPU6/Neo (GenePharma). A scrambled shRNA was used as a negative control and designated as shControl. The shRNA sequences were: for shPXN, 5′-CACCCCTGACGAAAGAGAAGCCTAATTCAAGAGATTAGGCTTCTCTTTCGTCAGGTTTTTTG-3′ (sense), 5′-GATCCAAAAAACCTGACGAAAGAGAAGCCTAATCTCTTGAATTAGGCTTCTCTTTCGTCAGG-3′ (anti-sense); for shRXN-AS1-L, 5′-CACCGCCCAGAGGAAATCAACAAGATTCAAGAGATCTTGTTGATTTCCTCTGGGCTTTTTTG-3′ (sense), 5′-GATCCAAAAAAGCCCAGAGGAAATCAACAAGATCTCTTGAATCTTGTTGATTTCCTCTGGGC-3′ (anti-sense); for shControl, 5′-CACCGTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTTG-3′ (sense), 5′-GATCCAAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGGAGAAC-3′ (anti-sense). Transient transfection was performed using Lipofectamine 3000 (Invitrogen) in accordance with the manufacturer’s instruction.
Construction of stable cell lines
To constructing PXN-AS1-L stably overexpressed A549 cells, pcDNA3.1-PXN-AS1-L or pcDNA3.1 was transfected into A549 cells and selected with neomycin (800 µg/ml) for 4 weeks. To constructing PXN-AS1-L stably depleted NCI-H1299 cells, shPXN-AS1-L or shControl was transfected into NCI-H1299 cells and selected with neomycin (1000 µg/ml) for 4 weeks.
RNA extraction and quantitative real-time PCR analysis (qPCR)
Total RNA was extracted from indicted tissues or cells using TRIzol Reagent (Invitrogen) in accordance with the manufacturer’s protocol. Reverse transcription was performed using the M-MLV Reverse Transcriptase (Invitrogen) in accordance with the manufacturer’s protocol. Quantitative real-time PCR (qPCR) was performed in the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the SYBR® Premix Ex Taq™ II kit (Takara, Dalian, China) in accordance with the manufacturer’s protocols. β-actin was used as an endogenous control. The primers sequences were: for PXN-AS1-L, 5′-ACCCATCCTCAACTACCCC-3′ (forward) and 5′-ACTTCGTCTGTGCCTTCTGC-3′ (reverse); for PXN, 5′-TATCTCAGCCCTCAACACGC-3′ (forward) and 5′-GGCAGAAGGCACAGACGAA-3′ (reverse); for β-actin, 5′-GGGAAATCGTGCGTGACATTAAG-3′ (forward) and 5′-TGTGTTGGCGTACAGGTCTTTG-3′ (reverse). The relative expression of RNAs was calculated using the comparative Ct method.
Western blot analysis
Total proteins were extracted using RIPA buffer (Beyotime, Shanghai, China). Identical quantities of proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto nitrocellulose filter membranes. After being blocked with 5% not-fat milk, the membranes were incubated with primary antibodies specific for PXN (Abcam, Hong Kong, China) or β-actin (Proteintech, Rosemont, IL, USA). After being washed, the membranes were incubated with IRdye 700-conjugated goat anti-mouse IgG or IRdye 800-conjugated goat anti-rabbit IgG and were detected using an Odyssey infrared scanner (Li-Cor, Lincoln, NE, USA).
Analysis of cell proliferation and apoptosis
Cell proliferation was detected using Glo cell viability assay and Ethynyl deoxyuridine (EdU) incorporation assay. For Glo cell viability assay, 3000 indicated NSCLC cells were seeded each well in 96-well plate. At indicated time, cell viability was detected using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) in accordance with the manufacturer’s protocol. EdU incorporation assay was carried out using the EdU kit (Roche, Mannheim, Germany) in accordance with the manufacturer’s protocol. The results were acquired and quantified with the Zeiss AxioPhot Photomicroscope (Carl Zeiss, Oberkochen, Germany) based on at least ten random fields. Cell apoptosis was detected using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay. Indicated NSCLC cells were treated with 25 ng/ml doxorubicin (Selleck, Houston, TX, USA) for 24 h. Then, cell apoptosis was detected using the TUNEL Cell Apoptosis Detection Kit (Beyotime) in accordance with the manufacturer’s protocol.
Cell migration assay
Cell migration was detected using transwell assay. 5 × 104 indicated NSCLC cells in serum-free medium were plated in the top chamber a 24-well transwell chamber (BD Biosciences, San Jose, CA, USA). Complete medium containing 10% fetal bovine serum was placed into the lower chamber. After incubation for 24 h, cells remaining on the top chamber were wiped off using a cotton swab, and the cells that had traversed the membranes were stained by crystal violet and counted.
Nude mouse xenograft assays
3 × 106 indicted NSCLC cells were subcutaneously injected into 6-week-old athymic BALB/c nude mice purchased from the Shanghai Experimental Animal Center of Chinese Academy of Sciences (Shanghai, China). Subcutaneous xenograft growth was measured weekly with a caliper, and the tumor volume was calculated as a × b2 × 0.5 (a, longest diameter; b, shortest diameter). The animal studies were approved by the ethics committee of the General Hospital of Chinese People’s Liberation Army (Beijing, China).
Immunohistochemistry (IHC)
For IHC, the subcutaneous xenografts were formalin-fixed, paraffin-embedded, and cut into 4 µm sections. The sections were incubated with primary antibodies specific for Ki67 (Abcam) or cleaved caspase-3 (Cell Signaling Technology, Boston, MA, USA). After being washed, the sections were incubated with horseradish peroxidase-conjugated second antibody (Abcam) and visualized using DAB Horseradish Peroxidase Color Development Kit (Beyotime).
Statistical analysis
All statistical analyses were performed using the GraphPad Prism Software. For comparisons, Student’s t test (two-sided), Wilcoxon signed-rank test, Mann–Whitney test, Pearson Chi square test, Log-rank test, and Pearson correlation analysis were performed as indicated. P values < 0.05 were considered as statistically significant.
Discussion
LncRNA PXN-AS1-L has 863 nucleotides in length. The gene encoding PXN-AS1-L locates at chromosome 12q24.23 and is reverse complementary to
PXN. PXN-AS1-L is recently identified to have oncogenic roles in HCC [
38]. In this study, we further studied the expression, roles, and mechanisms of action of PXN-AS1-L in NSCLC.
First, we found that PXN-AS1-L is up-regulated in NSCLC cell lines compared with normal bronchial epithelial cell line. Moreover, PXN-AS1-L is further up-regulated in NSCLC cell lines derived from metastatic sites (NCI-H1299 and SK-MES-1) compared with that derived from primary sites (NCI-H1975 and A549). In clinical tissues specimens, we also found that PXN-AS1-L is up-regulated in NSCLC tissues compared with noncancerous lung tissues and is further up-regulated in NSCLC bone metastases tissues. Analyses of the correlation between PXN-AS1-L expression and clinicopathological characteristics revealed that PXN-AS1-L was positively associated with tumor size, lymph nodes metastasis, advanced TNM stages, and poor prognosis. These data confirmed that PXN-AS1-L is up-regulated in NSCLC and implied that PXN-AS1-L may be involved in the progression of NSCLC. Whether the up-regulation of PXN-AS1-L in cancer is lung and liver cancer specific or cancer-popular need further investigation. Furthermore, multi-center prospective study investigating the correlation between the expression of PXN-AS1-L and prognosis of NSCLC patients would be more significant for the application of PXN-AS1-L for clinical outcome prediction.
Second, we investigated the in vitro and in vivo roles of PXN-AS1-L in NSCLC using gain-of-function and loss-of-function assays. Our results revealed that PXN-AS1-L overexpression increases NSCLC cell viability, promotes NSCLC cell proliferation, inhibits NSCLC cell apoptosis, and promotes NSCLC cell migration. Conversely, PXN-AS1-L knockdown decreases NSCLC cell viability, inhibits NSCLC cell proliferation, promotes NSCLC cell apoptosis, and represses NSCLC cell migration. Therefore, our data demonstrated that PXN-AS1-L also acts as an oncogene in NSCLC, similar to the roles of PXN-AS1-L in HCC. Whether the oncogenic role of PXN-AS1-L is lung and liver cancer specific or cancer-popular also need further investigation. Nevertheless, the up-regulation of PXN-AS1-L and oncogenic roles of PXN-AS1-L in NSCLC suggested that PXN-AS1-L may be a potential therapeutic target for NSCLC. Increasing evidences have shown that noncoding RNAs could be targeted by chemically modified complementary oligonucleotides, which are revealed to be effective treatment in animal models and clinical trials involving humans [
42,
43]. Therefore, developing chemically modified complementary oligonucleotides targeting PXN-AS1-L would be potential therapeutic strategy for NSCLC.
The focal adhesion protein PXN mediates critical signal transduction and plays important roles in cell survival and migration [
44,
45]. Due to the reverse complementation between
PXN-
AS1-
L and
PXN, we investigated whether PXN-AS1-L regulates PXN and whether PXN is the mediator of the oncogenic roles of PXN-AS1-L in NSCLC. In this study, we found that PXN-AS1-L up-regulated PXN expression. Similar to the expression pattern of PXN-AS1-L in NSCLC, PXN is also up-regulated in NSCLC tissues compared with noncancerous lung tissues and is further up-regulated in NSCLC bone metastases tissues. The expression of PXN-AS1-L is positively associated with that of PXN in NSCLC tissues. Furthermore, knockdown of PXN attenuated the oncogenic roles of PXN-AS1-L in NSCLC. All these data support the positive regulation of PXN by PXN-AS1-L and the importance of PXN in the oncogenic roles of PXN-AS1-L in NSCLC.
Authors’ contributions
XZ, WH, and ZZ designed the study; ZZ, ZP, JC, JW, YH, and KS carried out the experiments; XZ, WH, ZZ, ZP, and JC collected and analyzed the data. XZ, WH, and ZZ wrote the manuscript. All authors read and approved the final manuscript.